No Data
Modern Chinese Medicine Clarifies 60 Million-Share Option Scheme Capacity in 2024 Report
MODERN CHI MED: SUPPLEMENTAL ANNOUNCEMENTIN RELATION TO THE 2024 ANNUAL REPORT
Modern Chinese Medicine Group Co., Ltd.'s (HKG:1643) Popularity With Investors Under Threat As Stock Sinks 26%
Modern Chinese Medicine Group (HKG:1643) Strong Profits May Be Masking Some Underlying Issues
MODERN CHI MED: 2025 INTERIM REPORT
Zhongtai Securities: The gross profit margin of the traditional Chinese medicine sector is expected to recover in the second half of 2025. We are optimistic about leading OTC brands and innovative pipelines.
In the second half of 2025, the cost pressures in the traditional Chinese medicine sector are expected to gradually ease, leading to a recovery in gross margins. We are optimistic about OTC leaders and innovative pipelines that possess brand and channel advantages.